Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Firmagon Given By Prescription According To Spc

Related Conditions

Often studied with 18 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT06957691Phase 2Recruiting

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

NCT00930319CompletedPrimary

Effectiveness and Safety of Firmagon®

Showing all 2 trials

Research Network

Common Treatments

  • Firmagon Given By Prescription According To Spc1
  • Fezolinetant Reference Formulation1

Active Sponsors

  • Shehzad Basaria, M.D.1
  • Astellas Pharma US, Inc.1
  • Ferring Pharmaceuticals1
  • Ferring Arzneimittel GmbH1

Top Investigators

Related Conditions

  • Prostate Cancer With Bone Metastasis1
  • Vasomotor Symptoms Vms1
  • Hot Flashes1
  • Hot Flushes1
  • Vasomotor Symptoms1

Activity Timeline